KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Consensus Target Price from Analysts

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have earned a consensus recommendation of “Buy” from the eight analysts that are presently covering the company, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $24.83.

KALV has been the topic of several recent research reports. Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. Jones Trading reissued a “buy” rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Finally, JMP Securities assumed coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 target price for the company.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 6,669 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $11.97, for a total transaction of $79,827.93. Following the completion of the transaction, the chief executive officer now directly owns 287,811 shares of the company’s stock, valued at $3,445,097.67. This represents a 2.26 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Venrock Healthcare Capital Par acquired 14,562 shares of KalVista Pharmaceuticals stock in a transaction on Monday, February 3rd. The shares were bought at an average price of $9.22 per share, with a total value of $134,261.64. Following the completion of the transaction, the insider now directly owns 5,012,796 shares of the company’s stock, valued at $46,217,979.12. This trade represents a 0.29 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 261,055 shares of company stock worth $2,397,646 and sold 17,292 shares worth $184,625. Company insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in KALV. Hennion & Walsh Asset Management Inc. increased its stake in shares of KalVista Pharmaceuticals by 48.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 111,106 shares of the specialty pharmaceutical company’s stock worth $1,282,000 after acquiring an additional 36,279 shares during the last quarter. Rhumbline Advisers increased its position in KalVista Pharmaceuticals by 3.4% during the first quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company’s stock worth $611,000 after purchasing an additional 1,762 shares during the last quarter. GAMMA Investing LLC increased its position in KalVista Pharmaceuticals by 567.3% during the first quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company’s stock worth $51,000 after purchasing an additional 3,767 shares during the last quarter. Wellington Management Group LLP raised its stake in KalVista Pharmaceuticals by 4.2% during the fourth quarter. Wellington Management Group LLP now owns 122,863 shares of the specialty pharmaceutical company’s stock worth $1,041,000 after purchasing an additional 4,940 shares during the period. Finally, Frazier Life Sciences Management L.P. boosted its holdings in KalVista Pharmaceuticals by 32.5% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company’s stock valued at $41,400,000 after purchasing an additional 1,200,000 shares during the last quarter.

KalVista Pharmaceuticals Stock Performance

KALV stock opened at $12.00 on Wednesday. The firm has a fifty day moving average price of $11.32 and a 200 day moving average price of $10.31. KalVista Pharmaceuticals has a fifty-two week low of $7.30 and a fifty-two week high of $15.50. The firm has a market cap of $596.59 million, a PE ratio of -3.30 and a beta of 0.39.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).